Motilal Oswal's research report on Sun Pharma
Sun Pharma (SUNP) reported a slight miss at the operational level for 4QFY24. This was due to lower-than-expected sales in the ROW market and higher-than-expected opex for the quarter. SUNP has surpassed USD1b sales in the global specialty segment in FY24 vs. USD430m in FY20. This was backed by enhanced efforts towards product offerings/marketing activities in the regulated markets. We retain our FY25/FY26 estimates. We value SUNP at 30x 12M forward earnings to arrive at our TP of INR1,810. We expect an 18% earnings CAGR over FY24-26, driven by 12-13% sales CAGR in the Domestic Formulation (DF)/EM/ROW markets, 9% sales CAGR in the US market, and 220bp margin expansion.
Outlook
We retain our FY25/FY26 estimates. We value SUNP at 30x 12M forward earnings to arrive at our TP of INR1,810. We expect an 18% earnings CAGR over FY24-26, driven by 12-13% sales CAGR in the Domestic Formulation (DF)/EM/ROW markets, 9% sales CAGR in the US market, and 220bp margin expansion.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
